Mission and Values
Alvine is committed to developing biologics to target autoimmune/inflammatory diseases. Our initial focus targets celiac disease
Celiac disease is a gluten-induced autoimmune disease for which no drug therapy is presently available.
Alvine was founded based on technology licensed from Stanford University. Alvine Pharmaceuticals is the leader in the discovery and development of biologics targeting celiac disease. Alvine’s primary goal is to translate new knowledge about immune system pathogenesis into innovative products that improve the lives of patients.
New discoveries form basis for Alvine’s development candidates
Recent investigations have led to several important discoveries about celiac disease that provide targets for drug development. Among common dietary proteins, gluten is especially difficult to digest due to the abundance of the amino acids proline and glutamine. Proteases in the human stomach and small intestine are unable to cleave proteins at either of these amino acids efficiently. In genetically susceptable individuals, immunogenic gluten peptides are absorbed in the small intestine, where they trigger an autoimmune response. learn more about celiac disease >>
Alvine’s lead clinical product candidate
ALV003 is an orally administered combination of two proteases engineered to digest gluten. It targets the glutamine and proline residues that are common in gluten. ALV003 consists of a glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP).
Alvine, an autoimmune/ inflammation focused company
Alvine was founded with the mission of being the leader in developing innovative therapies for autoimmune/ inflammatory diseases. Alvine is already a leader in celiac disease science, pathophysiology, discovery, and development- and has built up the capabilities and knowledge to change the way celiac disease is treated. The Alvine team is dedicated, passionate, and displays great integrity, scientific excellence, and understanding of celiac disease. Our ultimate goal is to help improve the lives of people with autoimmune/ inflammatory diseases such as celiac disease.